Once the joint holder or the nominee or a family member reports an investor’s demise to a SEBI-regulated entity, the same will be updated across all such entities. A SEBI circular formalising this change is set to take effect from January 1, 2024.
Failure to update nomination on time will result in your MF folios getting frozen for all debit transactions. That is, you will not be able to redeem / make withdrawals from any of these investments. You can, however, continue investing in your existing folios.
Bristol Myers Squibb's Camzyos recommended by NICE for inherited heart condition pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.
Camzyos®▼(mavacamten) recommended for use on the NHS as an add-on treatment option for adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM)Mavacamten has been recommended by the National Institute for Health and Care Excellence (NICE), as an add-on to individually optimised standard care, for t.
Bristol Myers Squibb's Camzyos gets NICE recommendation pharmatimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmatimes.com Daily Mail and Mail on Sunday newspapers.